Johnson & Johnson reports data from Phase II NSCLC treatment trial - Clinical Trials Arena
Johnson & Johnson's Phase II SKIPPirr study of IV RYBREVANT in advanced NSCLC patients with EGFR ex19del or L858R mutations met primary endpoint of reducing infusion-related reactions (IRRs) to 22.5% with dexamethasone prophylaxis, compared to 67.4% historically. No Grade 3 or higher IRRs reported, and all IRRs were Grade 1 or 2.
Reference News
Johnson & Johnson's Phase II SKIPPirr study of IV RYBREVANT in NSCLC patients with EGFR exon 19 deletions or L858R mutations met primary endpoint of reducing infusion-related reactions (IRRs) to 22.5% with dexamethasone prophylaxis, compared to 67.4% historically. All IRRs were Grade 1 or 2, with no hospitalizations or Grade 3+ events reported.
Johnson & Johnson's Phase II SKIPPirr study of IV RYBREVANT in advanced NSCLC patients with EGFR ex19del or L858R mutations met primary endpoint of reducing infusion-related reactions (IRRs) to 22.5% with dexamethasone prophylaxis, compared to 67.4% historically. No Grade 3 or higher IRRs reported, and all IRRs were Grade 1 or 2.